This website uses cookies
Read our Privacy policy and Terms of use for more information.
Apr 28, 2026
•
1 min read
Sanofi's disease-modifying therapy can now be used in children as young as 1 year old, opening a new window to delay type 1 diabetes progression in the youngest patients.
Apr 27, 2026
Tandem's Control IQ+ becomes the only commercially available automated insulin delivery system approved for pregnancy use in the U.S.
Apr 24, 2026
The world's first one-year continuous glucose monitor is now available in Sweden, with Germany, Spain, and Italy to follow in the coming weeks.
The two have partnered to develop SC451, an investigational cell therapy aiming to restore the body’s ability to regulate glucose and eliminate the need for both insulin and immunosuppressive therapy.
Apr 23, 2026
The FDA has classified the Tandem Mobi insulin pump recall as Class I after a malfunction was found to disrupt insulin delivery and CGM communication.
Apr 16, 2026
Canadian MiniMed 780G users will have a new CGM option with the Simplera Sync, a smaller, calibration-free sensor designed for easier diabetes management.
Apr 14, 2026
3 min read
Niia Essential demonstrated proof of concept, strong performance and accuracy, and zero insulin delivery failures in its first clinical study.
Apr 9, 2026
Modular Medical's two-part tubeless patch design targets "almost-pumpers," with a planned U.S. commercial launch in Q2 2026.
Apr 8, 2026
2 min read
Gravity-related pressure changes are causing incorrect insulin delivery, posing serious risks of dangerous highs and low glucose levels.
Apr 6, 2026
4 min read
The MiniMed Fit wear study is testing adhesive performance across body locations as the device moves closer to commercialization.
Apr 3, 2026
These water-activated evaporative cooling cases help keep insulin and other medications within safe temperature ranges during travel and extreme heat.
Apr 2, 2026
The new insulin reduces injections from daily to once-a-week while maintaining effective glucose control demonstrated in phase 3 clinical trials.
Apr 1, 2026
The company plans to file an IDE with the FDA in Q2 2026 following successful trials in Brazil and Australia.
Mar 31, 2026
A new reporting feature for the iLet Bionic Pancreas helps clinicians quickly identify what’s working and where diabetes management can be improved.
Mar 30, 2026
The bill caps insulin costs, forces rebate transparency, and encourages competition to lower prescription prices overall.
Mar 18, 2026
MiniMed's upcoming screenless insulin pump is controlled entirely from a phone and start going to users later this year.
Mar 17, 2026
During the conference, Dexcom showcased upcoming device updates, new platform features, and future innovations designed to expand and enhance its CGM ecosystem.
Mar 13, 2026
Approximately 1.5% of Omnipod 5 pods are impacted by a tubing issue that may cause insulin to leak inside the device.
Mar 12, 2026
The collaboration allows Accu-Chek's CGM data to flow into the Glooko platform, giving care teams a single dashboard to review glucose trends in select European markets.
Results from the EVOLUTION 2 trial presented at ATTD showed 68% time in range using a fully closed-loop system—with no mealtime boluses and minimal time below range.
Mar 11, 2026
Sequel Med Tech's insulin pump moves beyond its limited release with new integrations and wider access for users and clinicians across the United States.
Mar 10, 2026
The CE Mark allows the MiniMed 780G insulin pump to pair with the 15-day Instinct CGM expanding sensor choice for people with diabetes in Europe.
The new Liberty feature allows people with type 1 diabetes to temporarily stop counting carbs or deliver boluses while CamAPS FX automatically manages glucose levels.
Mar 5, 2026
The world's smallest tubed AID system can now be controlled from Android phones, unlocking a massive untapped market.
Mar 3, 2026
The company behind the Eversense implantable CGM is one step closer to releasing a next-gen sensor that removes the requirement for an external transmitter.
